Patents Examined by John Mabry
  • Patent number: 11186563
    Abstract: Chiral acetyl-protected aminoethyl quinoline (APAQ), pyridine and imazoline ligands are disclosed that enable Pd (II)-catalyzed enantioselective arylation or heteroarylation of ubiquitous prochiral ?-methylene C—H bonds of aliphatic amides offers an alternative disconnection for constructing ?-chiral centers. Systematic tuning of the ligand structure reveals that a six-membered instead of a five-membered chelation of these types of ligands with the Pd(II) is important for accelerating the C(sp3)-H activation thereby achieving enantioselectivity for quinoline and pyridine ligands.
    Type: Grant
    Filed: March 20, 2017
    Date of Patent: November 30, 2021
    Assignee: The Scripps Research Institute
    Inventor: Jin-Quan Yu
  • Patent number: 11161845
    Abstract: Provided herein are compounds, pharmaceutical compositions comprising the compounds, methods of preparing the compounds, and methods of using the compounds and compositions in treating diseases or disorders in a subject where the subject is in need of an inhibitor of MEK where the Compound is according to Formula (I), where X1, R1, R2, R2a, R3, R3a, and R3b are as described herein.
    Type: Grant
    Filed: May 18, 2018
    Date of Patent: November 2, 2021
    Assignee: Nflection Therapeutics, Inc.
    Inventors: John Kincaid, Matthew Duncton
  • Patent number: 11149018
    Abstract: The present application relates to novel substituted N-arylethyl-2-aminoquinoline-4-carboxamide derivatives, to processes for preparation thereof, to the use thereof alone or in combinations for treatment and/or prevention of diseases, and to the use thereof for production of medicaments for treatment and/or prevention of diseases, especially for treatment and/or prevention of fibrotic and inflammatory disorders.
    Type: Grant
    Filed: April 4, 2018
    Date of Patent: October 19, 2021
    Assignees: Bayer Aktiengesellschaft, Bayer Pharma Aktiengesellschaft
    Inventors: Hartmut Beck, Raimund Kast, Mark Meininghaus, Chantal Fuerstner, Timo Stellfeld, Clemens-Jeremias Von Buehler, Lisa Dietz, Michaela Bairlein, Johanna Anlahr, Hannah Joerissen, Peter Hauff, Joerg Mueller, Karoline Droebner, Jens Nagel
  • Patent number: 11136296
    Abstract: The present application relates to novel substituted N-arylethyl-2-arylquinoline-4-carboxamide derivatives, to processes for preparation thereof, to the use thereof alone or in combinations for treatment and/or prevention of diseases, and to the use thereof for production of medicaments for treatment and/or prevention of diseases, especially for treatment and/or prevention of fibrotic and inflammatory disorders.
    Type: Grant
    Filed: April 4, 2018
    Date of Patent: October 5, 2021
    Assignees: Bayer Aktiengesellschaft, Bayer Pharma Aktiengesellschaft
    Inventors: Hartmut Beck, Raimund Kast, Mark Meininghaus, Lisa Dietz, Chantal Fuerstner, Timo Stellfeld, Sonja Anlauf, Clemens-Jeremias Von Buehler, Michaela Bairlein, Johanna Anlahr, Uwe Muenster, Carsten Terjung, Hannah Joerissen, Peter Hauff, Joerg Mueller, Karoline Droebner, Jens Nagel
  • Patent number: 11098043
    Abstract: This disclosure relates to compounds that are CBP inhibitor and methods of using such compounds in the treatment and diagnosis of diseases and disorders.
    Type: Grant
    Filed: July 13, 2018
    Date of Patent: August 24, 2021
    Assignee: University of Massachusetts
    Inventors: Wei Zhang, Alex Mugwiria Muthengi, Hailemichael O. Yosief
  • Patent number: 11078159
    Abstract: A compound, or a pharmaceutically acceptable salt or isomer thereof, of Formula I: wherein R is hydrogen, alkyl, substituted alkyl, alkenyl, or substituted alkenyl; R1 is hydrogen, alkoxy, or substituted alkoxy; R2 is hydrogen, alkyl, or substituted alkyl; and R3 is hydrogen, alkyl, or substituted alkyl.
    Type: Grant
    Filed: February 19, 2018
    Date of Patent: August 3, 2021
    Assignees: University of Pittsburgh—Of the Commonwealth System of Higher Education, Universite Le Havre Normandie
    Inventors: Abdelhadi Rebbaa, Sebastien Comesse, Adam Daich, Martin Lawson, Catalin Pintiala
  • Patent number: 11072568
    Abstract: Disclosed is a process for purifying one or more chemical constituents from plant matter using extraction with a fluid that is not a solvent, for example, with a vegetable oil. The extracted chemical constituents may then optionally be further processed by heating in order to induce desired chemical transformations. The extracted chemical constituents are also processed by concentrating at reduced pressure, for example, by distillation.
    Type: Grant
    Filed: August 14, 2017
    Date of Patent: July 27, 2021
    Assignee: Scientific Holdings, LLC
    Inventors: Jeffrey Charles Raber, Sytze Elzinga
  • Patent number: 11066386
    Abstract: The present invention provides compounds of Formula II or a pharmaceutically acceptable salts thereof, useful as a CGRP receptor antagonist.
    Type: Grant
    Filed: May 8, 2018
    Date of Patent: July 20, 2021
    Assignee: Eli Lilly and Company
    Inventors: David Andrew Coates, Simon James Richards, Adam Jan Sanderson
  • Patent number: 11066377
    Abstract: The present disclosure relates to a process for the production of aromatic primary amines, by reacting an aromatic dialdehyde with hydrogen and ammonia or an ammonia-liberating compound, in the presence of a hydrogenation catalyst and an amine, wherein the molar ratio of the amine to the aromatic dialdehyde is no less than 1:4 at the start of the reaction.
    Type: Grant
    Filed: February 4, 2020
    Date of Patent: July 20, 2021
    Assignee: RHODIA OPERATIONS
    Inventors: Peng Li, Floryan Decampo
  • Patent number: 11053206
    Abstract: Described herein is an hydrofluorocarboximidate of formula (I) where: RH is a linear or branched alkyl group comprising 1 or 2 carbon atoms and (a) Rf1 and Rf2 are independent-selected from a linear or branched perfluorinated alkyl group comprising 1-8 carbon atoms and optionally comprising at least one catenated atom selected from oxygen, nitrogen, or combinations thereof; or (b) Rf1 and Rf2 are connected to form a ring structure comprising a total of 4-8 carbon atoms and in addition to the nitrogen atom from the carboximidate the ring structure may optionally comprises at least one catenated atom selected from oxygen, nitrogen, or combinations thereof. A method of making the hydrofluorocarboximidate with improved yield is described as well as various uses for the hydrofluorocarboximidate of Formula (I).
    Type: Grant
    Filed: August 23, 2018
    Date of Patent: July 6, 2021
    Assignee: 3M Innovative Properties Company
    Inventor: Sean M. Smith
  • Patent number: 11045448
    Abstract: The present disclosure provides compounds represented by Formula (I): and the pharmaceutically acceptable salts and solvates thereof, wherein A, R1a, R1b, R1c, R1d, R2, R3, R8a, R8b, R10, X, Z2, m, and n are as defined as set forth in the specification. The present disclosure also provides compounds of Formula (I) for use to treat a condition or disorder responsive to menin inhibition such as cancer.
    Type: Grant
    Filed: March 30, 2018
    Date of Patent: June 29, 2021
    Assignee: THE REGENTS OF THE UNIVERSITY OF MICHIGAN
    Inventors: Shaomeng Wang, Angelo Aguilar, Shilin Xu, Liyue Huang, Jeanne Stuckey, Tianfeng Xu
  • Patent number: 11046675
    Abstract: The present disclosure generally relates to compounds useful as immunomodulators. Provided herein are compounds, compositions comprising such compounds, and methods of their use. The disclosure further pertains to pharmaceutical compositions comprising at least one compound according to the disclosure that are useful for the treatment of various pp diseases, including cancer and infectious diseases.
    Type: Grant
    Filed: March 26, 2018
    Date of Patent: June 29, 2021
    Assignee: Bristol-Myers Squibb Company
    Inventors: Kap-Sun Yeung, Denis R. St. Laurent, Jeffrey Lee Romine, Paul Michael Scola
  • Patent number: 11046664
    Abstract: Methods for extracting and concentrating cannabinoids using ultrasound-enhanced solvent extraction. Freshly harvested cannabis plant materials, which may be selectively chosen plant parts or the entire plant itself, are shredded to a particular particle size. The plant material is then mixed with a solvent to form a slurry, and thereafter subjected to ultrasound to release intracellular contents into the solvent. Filtering steps are then applied to remove biomass, waxes and chlorophyll. Water removal and solvent recovery steps are further applied to ultimately derive an extract having high concentrations of target cannabinoids, and in particular cannabidiol (CBD). The methods may be deployed on-site in batch or continuous flow processes, and may further be utilized to derive other types of materials from plants, such as essential oils.
    Type: Grant
    Filed: November 11, 2019
    Date of Patent: June 29, 2021
    Assignee: WORLD CLASS EXTRACTIONS, INC.
    Inventors: Anthony J. Durkacz, Mark T. Cullen
  • Patent number: 11046687
    Abstract: A novel polycyclic amide compound, preparation process and use thereof are provided. The compound has cytotoxic biological activity, particularly for the treatment and/or prevention of cell proliferative diseases such as cancer. This compound is a compound represented by Formula I or a pharmaceutically acceptable salt, solvate, polymorph, enantiomer or racemic mixture, prodrug and N-oxide thereof, wherein, R, R1-R3 are independently selected from hydrogen, C1-5 alkyl, or C1-5 having a hydroxyl group or a halogen, and may be bonded to each other to form a ring, Z is an arbitrary substituent group, X1 and X2 may be carbon or nitrogen respectively, Q is oxygen or sulfur. Compared to the existing known polycyclic amide compounds, the novel polycyclic amide compound has more potent cytotoxicity and can be used for the treatment of diseases such as tumors, cancers, Alzheimer's disease, autoimmune diseases, cataracts, psychological disorders, depression and/or anxiety.
    Type: Grant
    Filed: September 10, 2019
    Date of Patent: June 29, 2021
    Inventors: Wei Li, Anya Yang, Shangjin Yang
  • Patent number: 11033473
    Abstract: Provided is a hair restoration/growth stimulating agent containing at least one type of flavonoid represented by formula (I) as an active ingredient. Further provided is a hair restoration/growth stimulating agent containing at least one type of phenylpropanoid represented by formula (II) as an active ingredient.
    Type: Grant
    Filed: December 19, 2019
    Date of Patent: June 15, 2021
    Assignee: KINJIRUSHI CO., LTD.
    Inventors: Isao Okunishi, Tomoe Kato
  • Patent number: 11028105
    Abstract: Disclosed herein are borazine, borate, and azaborinine compounds and compositions, methods of making said compounds and compositions, and methods of forming aromatic difluorocarbon compounds and difluorocarbon compounds.
    Type: Grant
    Filed: June 28, 2019
    Date of Patent: June 8, 2021
    Assignee: THE REGENTS OF THE UNIVERSITY OF MICHIGAN
    Inventors: Nathaniel Szymczak, Jacob Geri
  • Patent number: 11019821
    Abstract: The invention relates to novel compounds of the formula (I) in which Aa, Ab, Ac, Ad, Q, R1 and n have the definitions given above, to their use as acaricides and/or insecticides for controlling animal pests and to processes and intermediates for their preparation.
    Type: Grant
    Filed: February 14, 2019
    Date of Patent: June 1, 2021
    Assignee: Bayer Aktiengesellschaft
    Inventors: Ruediger Fischer, Dominik Hager, Laura Hoffmeister, Matthieu Willot, Kerstin Ilg, Ulrich Goergens, Andreas Turberg
  • Patent number: 11021457
    Abstract: The present invention provides an isoindolone-imide ring-1,3-dione-2-ene compound, and a preparation method, a pharmaceutical composition and use thereof. Specifically, the present invention provides a compound of Formula (I) below or a pharmaceutically acceptable salt thereof, wherein Ar is an isoindolinone-imide group represented by Formula (II), L is absent or is a divalent, trivalent or tetravalent linking group, and X is a group represented by Formula (III). Definitions of the other groups are as described in the specification. The compound of Formula (I) is an autophagy modulators, particularly a mammalian ATG8 homolog modulator.
    Type: Grant
    Filed: May 17, 2018
    Date of Patent: June 1, 2021
    Assignee: WIGEN BIOMEDICINE TECHNOLOGY (SHANGHAI) CO., LTD.
    Inventors: Zhiyi Yao, Cheng Luo, Yuli Xie, Liyan Yue, Wei Wan, Yuanyuan Zhang, Hualiang Jiang, Kaixian Chen
  • Patent number: 11008334
    Abstract: K-Ras is the most frequently mutated oncogene in human cancer. Disclosed herein are compositions and methods for modulating K-Ras and treating cancer.
    Type: Grant
    Filed: December 19, 2019
    Date of Patent: May 18, 2021
    Assignee: The Regents of the University of California
    Inventors: Jonathan Ostrem, Ulf Peters, Kevan M. Shokat
  • Patent number: 11008332
    Abstract: A composition for preventing or treating an aging-related disease includes a novel decursin derivative as an active ingredient, wherein the novel decursin derivative has exhibited an excellent effect of inhibiting progerin expression and excellent effect of inhibiting binding between progerin and lamin A, and it has been confirmed that the novel decursin derivative prolongs the survival period of animal models in which progerin was induced.
    Type: Grant
    Filed: April 25, 2018
    Date of Patent: May 18, 2021
    Assignee: PRG S&TECH INC
    Inventors: Bum Joon Park, Gyu Yong Song, Yu Seok O, Jee Hyun Lee, Eun Ju Yun